Rupatadine oral solution improves rhino-conjunctive symptoms control in children with 6-11 years weighing ≥25 kg with persistent allergic rhinitis

Table 1 Table 1

Mean score reduction	Placebo (n=135)	Rupatadine (n= 131)	P-value
4TSS at 4 weeks	-2.4 (1.9)	-3.1 (2.1)	P < 0.01
4TSS at 6 weeks	-2.6( 2.0)	-3.4 (2.1)	P < 0.01
5TSS at 4 weeks	-2.7 (2.4)	-3.7 (2.5)	P < 0.01
5TSS at 6 weeks	-2.9 ( 2.5)	-4.0 (2.6)	P < 0.01

PRQLQ overall score showed statistical significant differences between RUP and placebo at 4 weeks (p=0.01) and 6 weeks (p<0.05). Adverse events were scarce in both treatment groups throughout the study. Somnolence was reported with a very low incidence (1.4% RUP) and no serious adverse events were reported.